Ian Turner is a successful CEO with prodigious international experience in high technology industries, specializing in the leadership of global organizations undergoing change. He has a record of corporate success in radiopharmaceuticals, nuclear industries, life sciences and medical devices.
Most recently, Turner served as CEO and President at Siemens where he was responsible for the global PETNET and Cyclotron businesses. PETNET operates the largest PET radiopharmaceutical network in the world with over 55 radiopharmacies in seven countries.
Previously, Turner was responsible for the radiopharmaceuticals business of the Australian Nuclear Science and Technology Organisation (ANSTO) in Australia, which is home to the OPAL (Open Pool Australian Lightwater) nuclear reactor. He successfully created and led the initiative for ANSTO to be the first international commercial supplier of Molybdenum-99 derived from low-enriched uranium. He also served on the Organisation for Economic Co-operation and Development (OECD) High-level Group on the Security of Supply of Medical Radioisotopes.
Today, Turner is the CEO of the TURNER Group and he serves on the Board of Coqui Pharma. The TURNER Group provides a broad range of professional business advice to Investment Bankers looking at global opportunities in Nuclear Medicine and Molecular Imaging. Coqui Pharma's mission is to provide a reliable supply of medical diagnostic and therapeutic radioisotopes in the USA.
Turner has Master's and Bachelor's degrees in Electronic Engineering from RMIT University and has a Company Directors Diploma from the AICD. He is a sought-after public speaker and the global authority on PET and SPECT Radiopharmaceuticals.
He has served on various boards in different countries, he is well published and has a number of USA and European patents